Mental Health DailyResearch. Evidence. Perspective.Published research on naltrexone.
A 2026 umbrella review of 16 systematic reviews covering 371 trials found strong medication evidence for tobacco and opioid use disorders, modest benefits for alcohol use disorder, and no ap…
Read articleThe endogenous opioid system has been a candidate target for novel anxiety treatments, but a 2026 placebo-controlled crossover fMRI study in 38 healthy volunteers ran opposite the hypothesis…
Read articleLisdexamfetamine remains the only FDA-approved medication for binge-eating disorder — a serious condition affecting roughly 1.2% of adults. A 2026 human laboratory study by McKee and colleag…
Read articleNaltrexone is a chemical initially synthesized in 1963 and patented thereafter by the pharmaceutical company Endo Laboratories in 1967. It is considered a substituted derivative of oxymorpho…
Read articleNaltrexone is a pure opioid receptor antagonist utilized principally for the treatment of alcohol and opioid dependence. As an opioid receptor antagonist, naltrexone competitively binds to m…
Read articleIn September 2014, the FDA recently approved a new weight loss drug Contrave. This drug is considered the third pharmaceutical treatment for obesity in the United States. Although it probabl…
Read article
